News


All series


All News

Pembrolizumab (Keytruda) has been granted an accelerated approval by the FDA for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell lung cancer, regardless of PD-L1 expression.

David M. Sabatini, MD, PhD, has been declared the winner of the 2017 Lurie Prize in Biomedical Sciences from the Foundation for the National Institutes of Health.

NYU Langone’s Perlmutter Cancer Center has announced that Ophira Ginsburg, MD, will be director of its new High-Risk Program, which will identify, study, and care for patients with hereditary syndromes that increase their risk for developing cancer.